Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Status:
Completed
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
The androgen receptor (AR) is expressed in 70-90 percent of primary breast tumors and in 75
percent of breast metastases. There is evidence to suggest that Androgen Receptor (AR) may be
a target in patients with advanced breast cancer. Breast cancer patients whose tumors do not
express the ER, PR or HER2 (triple negative) have very few options for treatment. Orteronel
is being developed as an endocrine therapy for relevant hormone-sensitive cancers such as
prostrate cancer and breast cancer. Triple-negative metastatic breast cancer patients with AR
expression could potentially benefit from anti-androgen therapy like orteronel.